Presented By: Julie Hoffman, ADN, RN, OCN Sylvia Wentzky, ADN, RN Bon Secours St. Francis Health System Greenville, South Carolina.

Slides:



Advertisements
Similar presentations
Utilization Patterns of Erythropoiesis Stimulating Agents Prescribed for Chemotherapy-Induced Anemia, and the Impact of the Outpatient Regimen on Subsequent.
Advertisements

Innovation ● Investigation ● Application
Innovation ● Investigation ● Application
A Retrospective Review Investigating the Feasibility of Acupuncture as a Supportive Care Agent in Children with Cancer Kathy Taromina, MS, LAc, Diane Rooney,
Rare Film Guide Slide Set. Clinical Trial Design for Pirfenidone Study Purpose of Study: To see if the use of pirfenidone decreases the loss of lung function.
Metoclopramide versus Hydromorphone for the ED Treatment of Migraine Headaches Justin Griffith, MD Mark Mycyk, MD Demetrios Kyriacou, MD, PhD ICEP Resident.
Good Help to Those in Need. ® The Dollars and $ense of Navigation: How to quantify your role Donna Moore Wilson, BSN, RN, CBCN Oncology Nurse Navigator.
©American Society of Clinical Oncology All rights reserved. Guideline Update.
Held in conjunction with the Association for Value-Based Cancer Care’s (AVBCC’s) First Annual Stakeholder Integration Conference.
Fosaprepitant and aprepitant
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
Sublingual Buprenorphine and Pain
Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice Janet Kelly, Pharm.D., BC-ADM February 22, 2005.
2010 UBO/UBU Conference Title: Common Coding Errors in IV Services Session: W
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
 Definition of Chemotherapeutic Drug Administration  Administration of Chemotherapeutic Agents  Dosage of chemotherapeutic administration  Equipment.
Interim LSU Hospital (ILH) Study 2012: Evaluating adherence to supportive care guidelines for patients admitted to ILH for neutropenic fever Edgar Castillo.
Chemotherapy Induced Nausea and Vomiting
Ginger for Chemotherapy-related Nausea in Cancer Patients Julie L. Ryan, PhD, MPH 1 C. Heckler, PhD 1, S.R. Dakhil, MD 2, J. Kirshner, MD 3, P.J. Flynn,
Prior Authorization Criteria for PDL Classes: Alzheimer’s Anti-emetics High Potency Statins Hormone Replacement Therapy Multiple Sclerosis – Tysabri Charles.
Introduction The treatment of relapsed ovarian cancer involves rechallenge with platinum based chemotherapy. One regimen commonly in use at the Christie.
Community Oncology Conference Thursday April 23 rd, 2015.
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
® From Bad to Worse: Comorbidities and Chronic Lower Back Pain Margaret Cecere JD, Richard Young MD, Sandra Burge PhD The University of Texas Health Science.
Amany M. Shebl Professor Of Medical-surgical Nursing Dean. Nursing Faculty, Mansoura University, Egypt.
New Drugbox Medication Ondansetron Ondansetron Trade Name:Zofran Drug Class:Antiemetic Clinical Uses:Prevention of nausea & vomiting.
A Phase II Trial of Perifosine in Patients with Chemo-Insensitive Sarcomas Study Update – November 2008 Dejka Araujo, MD MD Anderson Cancer Center, Houston,
CNYEMS 2008 Protocol Additions Phase 1 Medical Director, Daniel Olsson, DO Executive Director, Susie Surprenant Central New York EMS 50 Presidential Plaza.
® Introduction Changes in Opioid Use for Chronic Low Back Pain: One-Year Followup Roy X. Luo, Tamara Armstrong, PsyD, Sandra K. Burge, PhD The University.
Seminar in Palliative Care September 26 – October 02, 2010 Salzburg, Austria in Collaboration with.
Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice Janet Kelly, Pharm.D., BC-ADM February 24, 2004.
AprepitantAprepitant Division of Gastrointestinal and Coagulation Drug Products Division of Gastrointestinal and Coagulation Drug Products Center for Drug.
©American Society of Clinical Oncology All rights reserved. Antiemetics: American.
欢 迎 光 临欢 迎 光 临. NCCN Clinical Practice Guidelines in Oncology™ Melanoma Lili Yun nan biotherapy center
Mual Muntah Afifah Machlaurin>. Siapkan kertas Sebutkan titik yang bertanggung jawab terhadap respon mualmuntah ! 2. Sebutkan 4 mekanisme stimulasi.
CINVForum Web-symposium dedicated to chemotherapy induced nausea and vomiting in lung cancer patients Survey on CINV – Results Base: 168 registered physicians.
5 mins on last days of life and palliative care emergencies ! Dr. Ros Taylor Hospice Director Hospice of St. Francis Berkhamsted June 2012.
Drugs Used to Treat Nausea and Vomiting Chapter 34 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
CDRP Program Update UPMC McKeesport Program Steering Committee RTOG Meeting Toronto, Canada June 23 rd, 2006.
IOBS Triage System Overview Spring 2016 Barbara McAneny MD, CEO
Accessing Pharmaceuticals through Medicare: Part B versus Part D American Public Health Association Conference 2007 Washington DC, USA November 7,2007.
Hima Darapu, MD Princeton Baptist Medical Center Baptist Health systems Alabama.
JUST GIVE IT: a 2 phase study to audit the Immediate Management of Patients with Proven or Suspected Neutropenic Sepsis by Ally Gruber Acute Oncology Clinical.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.
University of Auckland Nursing 785 Assignment 3. Marc McLaughlin
Understanding Community Cancer Care.  Historically, cancer care occurred predominantly in hospital setting  A few decades ago, care migrated to the.
I N T HE N AME O F G OD Combination of Haloperidol, Dexamethasone, and Ondansetron, Reduces Nausea and Pain Intensity and Morphine Consumption after Laparoscopic.
ASCO’s Quality Training Program Project Title: Improving oral chemotherapy fulfillment processes and implementation of a pharmacist- managed oral chemotherapy.
CONTROLLING THE COSTS OF HEMOPHILIA
> 3 hours with > 5 blood draws Medical Emergency
SD Walter MD1, T Mahten MD2, JW Harbour MD1,3
Duration of Therapy of Colony Stimulating Factors in Oncology
Dr Rachel Hall Lisa Hammond, CNS Royal Bournemouth Hospital
Investment Opportunity and
Other Gastrointestinal Drugs
Antiemesis Premedications OVMC Guidelines High Risk Moderate Risk
Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.
Francis P. Bustos, MD, Benjamin R. Coobs, MD, Joseph T. Moskal, MD
Evaluation of Rasburicase Administration at University of Iowa Hospitals and Clinics Katie Gaspar, Ahmed Abdeldagir, Christine Behrendt, Michael Boller,
Presentation transcript:

Presented By: Julie Hoffman, ADN, RN, OCN Sylvia Wentzky, ADN, RN Bon Secours St. Francis Health System Greenville, South Carolina

The purpose of this Evidence Based Project was to compare the cost effectiveness of two anti-nausea medications: ALOXI and ZOFRAN for patients receiving highly emetogenic chemotherapy regimens, such as Cisplatin.

 Bon Secours St. Francis Health System Outpatient Infusion Center  Retrospective 3 month chart review  Solid tumor types  100 adult patients

 Gender  Age  Diagnosis  Types of Lung Cancer Treatments  Antiemetics in Cisplatin Protocols

ALOXI- 8% Total Cost Savings Increased Patient Satisfaction Decreased Nursing Time ZOFRAN- Lower Patient Satisfaction Increased Clinic Visits Increased Nursing Time Aloxi:  IV push 1 dose day of chemo  Nursing time - 5 minutes  Supplies – needle & syringe Zofran:  IVPB treatment day  2 extra days of IV fluids and daily Zofran IVPB  Nursing time – 6.5 hours  Supplies – IV tubing

The cost analysis demonstrated that selecting Aloxi on Day 1 of the chemotherapy treatment impacted:  Cost  Patient Satisfaction  Nurse Time Limitations of this study included a small sample size, retrospective nature, and selective diagnosis of Lung Cancer.

 Product Availability  Provider Changes & Preferences  Protocol Changes ◦ Dexamethasone 10 mg IVP ◦ Zofran 8 mg IVP ◦ Emend 150 mg IVPB  3 Month Retrospective Analysis (2014) ◦ 12 Lung Cancer Patients – Cisplatin Treatment ◦ 1 Patient Needed Hydration

DeLeon, A. (2006, October). Palonosetron (Aloxi): A Second Generation 5HT3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting. Baylor University Medical Center Proceeding, 19(4), Retrieved from Feinberg, B.A., Gilmore, J., Haislip, S., Gondesen, T., Saleh, N., Lenz, W. (2009, February). Data-Driven Medical Decision-Making in Managing Chemotherapy-Induced Nausea and Vomiting, Community Oncology, Retrieved from National Comprehensive Cancer Network. (2011). NCCN Clinical Practice Guilelines in Oncology (NCCN Guidelines) Antiemesis (Version ). Fort Washington, PA: Ettinger, David S., et al. Tarricone, R., & Girolami, F. (2005). Economic Evaluation of a New Antiemetic Drug – Palonosetron Versus Ondansetron, Clinical Drug Investiation, 25 (9), Retrieved from

Bon Secours St. Francis Health System Outpatient Infusion Center Greenville, South Carolina JULIE HOFFMAN, ADN, RN, OCN SYLVIA WENTZKY, ADN, RN TRACY FASOLINO, PhD, FNP, ACHPN